HHSN261201400048C; TOPIC 309 ? ?DEVEL.OF.LOW COST,SMALLSAMPLE MULTI-ANAL.TECH.FORCANCER DIAGNOSIS,PROGNOSIS&EARLY DETECTION?;TITLE: DEPLOYMENT.OF.PROTOTYPE SYSTEM FOR DETECTION OF MULTI. ANAL. IN SMAL

该提案将建立在第一阶段的成功努力的基础上，第一阶段的成功努力描述了该技术的特点， 检测的准确性和限度，并提供患者粘膜活检样本的概念验证数据 结直肠癌我们的目标是（1）开发一个原型分析系统， 技术，包括自动化，软件和数据分析;（2）在临床样品上测试原型， 与学术实验室合作，以证明临床实用性和优于分析电流 技术. 我们的合作者包括Jedd Wolchok（纪念斯隆凯特琳癌症中心），他领导了以下临床工作： 突破性的癌症免疫疗法ipilimumab和nivolumab，道格拉斯权（Ragon研究所），他的实验室 具有粘膜免疫学方面的专业知识和丰富的经验，与Enumeric的技术;伊丽莎白希尔曼 （哥伦比亚大学），他在开发新型光学成像系统方面拥有专业知识; Jason Ruan（VigeneTech） 他是图像分析和软件开发方面的专家，Paul和Doug Sabin（Fikst）是 在生产发展中。 使用Enumeric的平台来了解驻留组织中的细胞功能和对治疗的反应， 可能对早期癌症诊断、了解疾病机制产生重大影响， 进展，并最终开发新的，有效的和安全的免疫疗法。

This proposal will build on the successful efforts from Phase I, which served to characterize the technology's accuracy and limits of detection and provide proof of concept data on mucosal biopsy samples from patients with colorectal cancer. We aim to (1) Develop a prototype analytical system incorporating Enumeral's technology, including automation, software and data analysis and (2)Test prototypes on clinical samples in collaborating academic laboratories to demonstrate clinical utility and advantages over analytical current techniques. Our collaborators include Jedd Wolchok (Memorial Sloan Kettering Cancer Center), who led clinical efforts for breakthrough cancer immunotherapies ipilimumab and nivolumab, Douglas Kwon (Ragon Institute), whose lab has expertise in mucosal immunology and extensive experience with Enumeral's technology; Elizabeth Hillman (Columbia University), who has expertise in developing novel optical imaging systems; Jason Ruan (VigeneTech) who is an expert in image analysis and software development, and Paul and Doug Sabin (Fikst) who are experts in produce development. The use of Enumeral's platform to understand cellular function and responses to therapy in resident tissues can potentially have a significant impact on early cancer diagnosis, understanding mechanisms of disease progression, and, ultimately development of novel, effective, and safe immunotherapies.